AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Bicara Therapeutics: HC Wainwright Downgrades to Buy, PT $41 from $44.
ByAinvest
Friday, May 16, 2025 7:17 am ET1min read
Bicara Therapeutics: HC Wainwright Downgrades to Buy, PT $41 from $44.
Bicara Therapeutics (BCRT) has received a mixed signal from HC Wainwright & Co. The firm has downgraded its rating for Bicara Therapeutics from "Buy" to "Buy" while revising the price target from $44.00 to $41.00. The downgrade and adjustment were announced on May 16, 2025, by Robert Burns, an analyst at HC Wainwright & Co.The price target reduction reflects a slight tempering of optimism regarding Bicara Therapeutics' growth trajectory. Despite the downgrade, the "Buy" rating indicates that HC Wainwright & Co. remains bullish on the company's prospects. Investors are advised to consider this information when evaluating their investment decisions.
Wall Street analysts have forecasted varying price targets for Bicara Therapeutics Inc (BCRT). The average target price, based on the consensus of seven analysts, is $39.14, with a high estimate of $42.00 and a low estimate of $33.00. This average target price implies an upside of 84.42% from the current price of $19.89.
The consensus recommendation from eight brokerage firms is currently 1.6, indicating an "Outperform" status. This rating scale ranges from 1 to 5, where 1 signifies a "Strong Buy" and 5 denotes a "Sell."
Investors should closely monitor Bicara Therapeutics' performance and any updates from HC Wainwright & Co. to make informed decisions.
References:
[1] https://www.gurufocus.com/news/2866140/enliven-therapeutics-elvn-target-price-raised-by-hc-wainwright-co-elvn-stock-news
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet